TEMPUS LABS, INC.

TEMPUS LABS, INC. has been granted 63 US utility patents between 2019 and 2024, placing TEMPUS LABS, INC. at rank #5,478 across all assignees tracked by PlainPatent. This portfolio spans 20 distinct Cooperative Patent Classification (CPC) subclasses, averaging 33.7 claims per patent with primary concentration in G16H (HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA). As a US Corporation, TEMPUS LABS, INC. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 58.5/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 62 grants, compared with 1 in the 2015–2019 window — a +6100% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. TEMPUS LABS, INC.'s 33.7 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while a multi-domain presence across 20 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark TEMPUS LABS, INC. against peers pursuing similar technology classes.